Storia in 9 fonti

'Completely out of scope': Experts weigh in on proposed US tariffs on generic drugs

Experts have hinted that the proposed US decision of tariffs on generic drugs in the pharmaceutical sector is "out of scope" after US President Donald Trump made the announcement on Wednesday.

Raccontata da

timesofindia.indiatimes.com

hindustantimes.com

newsbytesapp.com

thehindubusinessline.com

theprint.in

economictimes.indiatimes.com

scmp.com

timesofoman.com

scroll.in

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

timesofoman.comStai leggendo4 g fa

'Completely out of scope': Experts weigh in on proposed US tariffs on generic drugs

Experts have hinted that the proposed US decision of tariffs on generic drugs in the pharmaceutical sector is "out of scope" after US President Donald Trump made the announcement on Wednesday.

originale

Timeline cronologica

mercoledì 22 luglio 2026·timesofindia.indiatimes.com
Trump announces 0% tariff on generic medicines for two years; 200% thereafter
US President Donald Trump on Tuesday announced a phased tariff regime on imported generic medicines, saying they will continue to enter the United States duty-free for two years…
mercoledì 22 luglio 2026·hindustantimes.com
0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines
In 2025, India exported USD 9.7 billion worth of pharmaceuticals to the US, accounting for 38 per cent of its total global pharma exports of USD 25.8 billion. | India News

'Completely out of scope': Experts weigh in on proposed US tariffs on generic drugs

Confronto fonti

'Completely out of scope': Experts weigh in on proposed US tariffs on generic drugs

Timeline cronologica

Trump announces 0% tariff on generic medicines for two years; 200% thereafter

0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines

Trump’s proposed generic drug tariffs ‘not practical’, says Indian pharma; US consumers will pay the price

Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive

Indian pharma firms may yet survive Trump's 200% tariff bombshell

0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines

Trump threatens tariff on generic medicines: Should India be worried?

0%, 100%, then 200%: How Trump's new generic drug tariff plan could hit India

Trump threatens tariff on generic medicines: Should India be worried?

0, 100, 200: How Trump's latest generic medicines tariffs could affect India

Trump’s proposed generic drug tariffs ‘not practical’, says Indian pharma; US consumers will pay the price

0% now, 100% in 2 years, 200% by 2029—US plan for generic pharma tariffs & what it means for India

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?

Trump’s 100% generic drug duty threatens US low-cost supply

200% Trump tariff shock? India’s cheap pills may still beat US rivals

Indian pharma firms may yet survive Trump's 200% tariff bombshell

Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors

Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive

What would 200% US tariffs on generic drugs mean for China’s pharmaceutical industry?

US tariffs could raise drug prices, squeeze Indian generics

Pharma companies in a flux over Trump's 200% tariff move on generics

Trump's 200% generic drug tariff threat puts $9.7 billion Indian pharma exports at risk; industry says reshoring not practical

'Completely out of scope': Experts weigh in on proposed US tariffs on generic drugs

‘Expect India to be concerned’: US official as Trump announces 200% tariffs on generic drugs